Pharma-Bio Serv reports July 31, 2025 results

Pharma-Bio Serv, Inc. filed a current report to disclose that it issued a press release announcing its results of operations for the three and nine months ended July 31, 2025.

Rhea-AI Filing Summary

Pharma-Bio Serv, Inc. filed a current report to disclose that it issued a press release announcing its results of operations for the three and nine months ended July 31, 2025. The press release is furnished as Exhibit 99.1 to the report, providing the detailed financial and operating results for that period. The company clarifies that this information, including Exhibit 99.1, is furnished rather than filed, meaning it is not subject to certain liability provisions under the Exchange Act or automatically incorporated into other securities filings. The report is signed on behalf of the company by Pedro J. Lasanta, its Chief Financial Officer, Vice President Finance and Administration, and Secretary.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Pharma-Bio Serv (PBSV) report in this 8-K filing?

The company reported that it issued a press release announcing its results of operations for the three and nine months ended July 31, 2025, which is furnished as Exhibit 99.1.

Which period do Pharma-Bio Serv (PBSV)'s reported results cover?

The results discussed in the press release cover the three and nine months ended July 31, 2025.

Where can investors find the detailed financial results for Pharma-Bio Serv (PBSV)?

Detailed financial and operating results are contained in the press release attached as Exhibit 99.1 to the report.

Is the Pharma-Bio Serv (PBSV) earnings press release considered filed with the SEC?

No. The company states that the information provided under Item 2.02, including Exhibit 99.1, is furnished and not filed for purposes of Section 18 of the Exchange Act.

Who signed the Pharma-Bio Serv (PBSV) 8-K report?

The report was signed by Pedro J. Lasanta, who serves as Chief Financial Officer, Vice President Finance and Administration, and Secretary of Pharma-Bio Serv, Inc.

What exhibits are included with this Pharma-Bio Serv (PBSV) 8-K?

The report includes Exhibit 99.1, a press release dated September 15, 2025, and Exhibit 104, the cover page Interactive Data File embedded within the Inline XBRL document.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/15/2025 - 05:27 PM Learn about SEC filing dates

0001304161false00013041612025-09-152025-09-15iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 15, 2025

Pharma-Bio Serv, Inc.

(Exact name of registrant as specified in its charter)

Delaware		0-50956		20-0653570
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

6 Road 696, Dorado, Puerto Rico		00646
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (787) 278-2709 

_________________________________________

(Former name or former address, if changed since last report) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class Trading Symbol(s) Name of each exchange on which registered

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On September 15, 2025, Pharma-Bio Serv, Inc. (the “Company”) issued a press release announcing its results of operations for the three and nine months ended July 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated September 15, 2025.
104		Cover page Interactive Data File (embedded within the Inline XBRL document).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PHARMA-BIO SERV, INC.
Date: September 15, 2025	By:	/s/ Pedro J. Lasanta
		Pedro J. Lasanta
		Chief Financial Officer, Vice President Finance and Administration and Secretary

3